
Frank Kloprogge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1059405/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An automated approach to identify scientific publications reporting pharmacokinetic parameters. Wellcome Open Research, 2021, 6, 88.	0.9	7
2	Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. Journal of Antimicrobial Chemotherapy, 2021, 76, 2252-2259.	1.3	21
3	Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. BMJ Open, 2021, 11, e052885.	0.8	0
4	Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial. BMJ Open, 2021, 11, e047185.	0.8	0
5	Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial. BMJ Open, 2021, 11, e047185.	0.8	5
6	Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model. Antibiotics, 2021, 10, 1515.	1.5	8
7	Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis. Open Forum Infectious Diseases, 2020, 7, ofaa218.	0.4	11
8	Ethambutol disposition in humans: Challenges and limitations of whole-body physiologically-based pharmacokinetic modelling in early drug development. European Journal of Pharmaceutical Sciences, 2020, 150, 105359.	1.9	3
9	Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?. Journal of Antimicrobial Chemotherapy, 2019, 74, 3530-3536.	1.3	2
10	Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. Scientific Reports, 2019, 9, 13228.	1.6	16
11	Revising Pediatric Vancomycin Dosing Accounting for Nephrotoxicity in a Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	19
12	Pharmacokinetic-pharmacodynamic modelling to investigate <i>in vitro</i> synergy between colistin and fusidic acid against MDR <i>Acinetobacter baumannii</i> . Journal of Antimicrobial Chemotherapy, 2019, 74, 961-969.	1.3	6
13	Key acceptability attributes of orodispersible films. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 125, 131-140.	2.0	33
14	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Medicine, 2018, 15, e1002579.	3.9	47
15	Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation. British Journal of Clinical Pharmacology, 2015, 80, 642-653.	1.1	29
16	Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border. Antimicrobial Agents and Chemotherapy, 2015, 59, 6375-6384.	1.4	27
17	Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Journal of Antimicrobial Chemotherapy, 2014, 69, 3033-3040.	1.3	22
18	Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda. Antimicrobial Agents and Chemotherapy, 2013, 57, 5096-5103.	1.4	41

#	Article	IF	CITATIONS
19	Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malaria Journal, 2012, 11, 293.	0.8	38